Erasca Entered into a Clinical Trial Collaboration and Supply Agreement with Eli Lilly to Evaluate ERAS-601 + Cetuximab for Cancer
- The company collaborated to evaluate Eli Lilly’s ERAS-601 (SHP2 inhibitor) in an ongoing P-I/IIb (FLAGSHP-1) PoC trial as monothx. and in combinations with Erbitux (cetuximab) in patients with triple wildtype (KRAS/NRAS/BRAF wildtype), metastatic CRC and HPV advanced HNSCC
- The study will be sponsored by Erasca. Lilly is supplying cetuximab at no cost. Erasca signed CTCSAs with Lilly and Pfizer to evaluate cetuximab and Braftovi (encorafenib) in combination with Erasca’s ERAS-007 (ERK1/2 inhibitor) in the P-Ib/II (HERKULES-3) trial
- Additionally, ERAS-601 + cetuximab improved anti-proliferative efficacy and reduced tumor growth compared to either treatment alone in models of HPV- HNSCC and triple wildtype CRC
Ref: GlobalNewswire | Image: Erasca
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.